Soleno Therapeutics Stock Today
| SLNO Stock | USD 57.22 0.56 0.97% |
Performance9 of 100
| Odds Of DistressLess than 25
|
Soleno Therapeutics is selling at 57.22 as of the 26th of November 2024; that is 0.97 percent decrease since the beginning of the trading day. The stock's open price was 57.78. Soleno Therapeutics has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Soleno Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of November 2014 | Category Healthcare | Classification Health Care |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. The company has 43.12 M outstanding shares of which 6.17 M shares are at this time shorted by private and institutional investors with about 8.05 trading days to cover. More on Soleno Therapeutics
Moving against Soleno Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Soleno Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Anthony Wondka | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSoleno Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Soleno Therapeutics' financial leverage. It provides some insight into what part of Soleno Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Soleno Therapeutics (SLNO) is traded on NASDAQ Exchange in USA. It is located in 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 and employs 33 people. Soleno Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.47 B. Soleno Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 43.12 M outstanding shares of which 6.17 M shares are at this time shorted by private and institutional investors with about 8.05 trading days to cover.
Soleno Therapeutics currently holds about 24.07 M in cash with (24.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Soleno Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Soleno Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Soleno Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Soleno Therapeutics. Please pay attention to any change in the institutional holdings of Soleno Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Soleno Ownership Details
Soleno Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 1 M | |
| Alyeska Investment Group, L.p. | 2024-09-30 | 976.1 K | |
| Fmr Inc | 2024-09-30 | 665.4 K | |
| Holocene Advisors, Lp | 2024-09-30 | 594.4 K | |
| Sofinnova Ventures | 2024-06-30 | 554.4 K | |
| Tcg Crossover Management, Llc | 2024-09-30 | 550 K | |
| Geode Capital Management, Llc | 2024-09-30 | 540.3 K | |
| Samlyn Capital, Llc | 2024-09-30 | 511.8 K | |
| Westfield Capital Management Company, Lp | 2024-09-30 | 495.7 K | |
| Vivo Capital, Llc | 2024-09-30 | 6.3 M | |
| The Carlyle Group Inc | 2024-09-30 | 4.1 M |
Soleno Therapeutics Historical Income Statement
Soleno Stock Against Markets
Soleno Therapeutics Corporate Management
| Kristen MS | Senior Operations | Profile | |
| Dr MBA | Senior Development | Profile | |
| Patricia MPH | Senior Affairs | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Meredith MBA | Chief Officer | Profile | |
| Anish MD | CEO and President | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.